CN Bio - About the company
CN Bio is a series B company based in Cambridge (United Kingdom), founded in 2009. It operates as a Develops organ-on-a-chip platforms for drug discovery. CN Bio has raised $71.2M in funding from CITIC, with a current valuation of £*****. The company has 43 active competitors, including 22 funded and 1 that has exited. Its top competitors include companies like Emulate, Hesperos and Numa Biosciences.
Company Details
Develops organ-on-a-chip platforms for drug discovery. The PhysioMimix OOC benchtop device is a Lab-on-a-Chip system that helps in vitro studies in fields including oncology, infectious diseases, metabolism, and inflammation, develop therapeutic antibodies/proteins, and cellular therapies, to investigate drug metabolism, toxicity, and drug-drug interactions. Also have Liver-On-a-Chip, barrier models, and others.
- Website
- cn-bio.com
- Social
- Email ID
- *****@cn-bio.com
- Phone Number
- +44 **********
- Registered Address
- 30 UPPER HIGH STREET,THAME,OXFORDSHIRE,OX9 3EZ
Key Metrics
Founded Year
2009
Location
Cambridge, United Kingdom
Stage
Series B
Total Funding
$71.2M in 13 rounds
Latest Funding Round
Post Money Valuation
£***** as on Jul 26, 2024
Ranked
2nd among 43 active competitors
Annual Revenue
£1M - £10M as on Dec 31, 2024
Employee Count
58 as on Jun 30, 2026
Legal entities associated with CN Bio
CN Bio is associated with 3 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Cn Bio Innovations Limited CIN: 6517359 , United Kingdom, Active | Feb 27, 2008 | £1M - £10M (As on Dec 31, 2024) | 49 (As on Dec 31, 2024) | |
CN Bio Innovations Ltd CIN: 6517359 , Germany, Active | Feb 27, 2008 | £1M - £10M (As on Dec 31, 2024) | 43 (As on Dec 31, 2023) | |
CN BIO INNOVATIONS, INC. CIN: 6772402 , United States, Active | May 02, 2022 | - | - | - |
Sign up to download CN Bio's company profile
CN Bio's funding and investors
CN Bio has raised a total funding of $71.2M over 13 rounds. Its first funding round was on 2011. Its latest funding round was a Series B round on Apr 23, 2024 for $*****. 2 investors participated in its latest round. CN Bio has 14 institutional investors and 1 angel investor.
Here is the list of recent funding rounds of CN Bio:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 23, 2024 | 4468360 | Series B | 7438479 | 6461302 | 4958451 | 7034380 |
Mar 02, 2021 | 6210750 | Grant (prize money) | 3023673 | 8345537 | 9783295 | |
Feb 18, 2021 | 9928339 | Series A | 9942764 | 4672179 | 1829091 | 2842833 |
Access funding benchmarks and valuations. Sign up today!View details of CN Bio's funding rounds and investors
CN Bio's founders and board of directors
Founder? Claim ProfileCN Bio's Board of Directors
CN Bio's board has 8 active members. Maureen Sheila Helen Coleman and Paul Robert Brooks are part of team and Yuexing Su, Hok Hei Charles Chong, Michael David Courtney Scales, Wang Yin, Andy Tse Po Shing and Tong Cheuk Fung are independent board members.Here is the list of CN Bio's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
urtvggw | Team | - | Current | 1y 4m |
Investor | - | Current | 16y 2m | |
Independent board member | - | Current | 12y 1m | |
rjaozrt | Independent board member | - | Current | 6y 4m |
smyhgc{ | Independent board member | - | Current | 5y 6m |
qkctomg | Independent board member | - | Current | 1y 2m |
yzurfgi | Independent board member | - | Current | 4y 8m |
xtrteno | Independent board member | - | Current | 7y 6m |
CN Bio's employee count trend
CN Bio has 58 employees as of Jun 26. Here is CN Bio's employee count trend over the years:
Uncover CN Bio's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
CN Bio's Competitors and alternates
Top competitors of CN Bio include Emulate, Hesperos and Numa Biosciences. Here is the list of Top 10 competitors of CN Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Emulate 2013, Boston (United States), Series E | Developer of in vitro models for drug development | $204M | 58/100 | |
2nd | CN Bio 2009, Cambridge (United Kingdom), Series B | Develops organ-on-a-chip platforms for drug discovery | $71.2M | 58/100 | |
3rd |  Hesperos 2015, Orlando (United States), Funding Raised | Developer of organ-on-a-chip solutions for preclinical testing | - | 53/100 | |
4th | Numa Biosciences 2007, Woodinville (United States), Acquired | Developer of platform for generating small segments of human tissues and organs in microfluidic chips | $10.7M | 50/100 | |
5th | Mimetas 2013, Leiden (Netherlands), Series B | Develops microfluidics-based organ-on-a-chip tissue models | $28.9M | 45/100 | |
6th | _1574840379393.png?devicePixelRatio=2&height=30&width=30){kind=logo} Obatala Sciences 2017, New Orleans (United States), Series A | Provider of research enabling products and services to research centers | $3.54M | 43/100 | |
7th |  Cellbox Labs 2020, Riga (Latvia), Seed | Provider of organ-on-chip platform for drug discovery and development | $1.01M | 43/100 | |
8th | Developer of a device for in vitro cancer testing using a microfluidic chip | $11.2M | 42/100 | ||
9th |  Mepsgen 2019, Seoul (South Korea), Series C | Developer of human organ model chips for pharmaceutical development | $29.3M | 40/100 | |
10th | Developer of microfluidic devices for industrial applications | $14M | 40/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on CN Bio's competitors? Click here to see the top ones
CN Bio's Investments and acquisitions
CN Bio has made no investments or acquisitions yet.
Reports related to CN Bio
Here is the latest report on CN Bio's sector:
News related to CN Bio
Filter this listMedia has covered CN Bio for a total of 2 events in the last 1 year, 2 of them have been about company updates.
•
CN Bio launches all-in-one Organ-on-a-chip systemEuropean Pharmaceutical Manufacturer•Oct 15, 2025•CN Bio
•
CN Bio enhances ADME services with computational modeling for accelerated drug discoveryEuropean Pharmaceutical Manufacturer•Sep 02, 2025•CN Bio
•
CN Bio and Pharmaron Establish Long-Term Strategic PartnershipBusiness Wire•Apr 24, 2025•Pharmaron, CN Bio
•
CN Bio Launches PhysioMimix DILI Assay Kit: Human 24, for Enhanced Preclinical Toxicology TestingBusiness Wire•Feb 04, 2025•CN Bio
•
•
•
CN Bio Raises $21 Million Series B FinancingEuropean Pharmaceutical Manufacturer•Apr 23, 2024•CN Bio, Pharmaron, CN Innovations
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about CN Bio
Explore our recently published companies
- Peak Asphalt - United States based, 1997 founded, Unfunded company
- Imagicle - Massarosa based, 2010 founded, Unfunded company
- iDO Devices - Noida based, 2025 founded, Seed company
- Onviant - 2018 founded, Unfunded company
- Apprentice - Tel Aviv-Yafo based, 2023 founded, Funding Raised company
- GeoHeim - Seoul based, 2020 founded, Funding Raised company
